S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Better Than Oil Stocks (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Better Than Oil Stocks (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Better Than Oil Stocks (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Better Than Oil Stocks (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Better Than Oil Stocks (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Better Than Oil Stocks (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Better Than Oil Stocks (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Better Than Oil Stocks (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Better Than Oil Stocks (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Better Than Oil Stocks (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Better Than Oil Stocks (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Better Than Oil Stocks (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
NASDAQ:RLMD

Relmada Therapeutics (RLMD) Stock Forecast, Price & News

$3.10
+0.05 (+1.64%)
(As of 10/3/2023 ET)
Compare
Today's Range
$3.01
▼
$3.16
50-Day Range
$2.48
▼
$3.79
52-Week Range
$1.81
▼
$36.15
Volume
82,608 shs
Average Volume
272,111 shs
Market Capitalization
$93.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.80
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Relmada Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
248.4% Upside
$10.80 Price Target
Short Interest
Bearish
2.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.45
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.69) to ($3.24) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

335th out of 966 stocks

Biotechnology Industry

11th out of 40 stocks

See Top Rated MarketRank™ Stocks Here

RLMD stock logo

About Relmada Therapeutics (NASDAQ:RLMD) Stock

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

RLMD Price History

RLMD Stock News Headlines

September 26, 2023 | finance.yahoo.com
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
September 21, 2023 | finance.yahoo.com
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
October 4, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
September 20, 2023 | benzinga.com
Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study
September 20, 2023 | marketwatch.com
Relmada Therapeutics Shares Rise 18% After Positive Trial Data for REL-1017
September 20, 2023 | markets.businessinsider.com
Relmada Therapeutics: Long-term Study With REL-1017 Shows Rapid, Sustained Therapeutic Effects
September 20, 2023 | finance.yahoo.com
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
September 1, 2023 | msn.com
Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout
October 4, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
August 23, 2023 | markets.businessinsider.com
Mizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
August 16, 2023 | finance.yahoo.com
Following a 88% decline over last year, recent gains may please Relmada Therapeutics, Inc. (NASDAQ:RLMD) institutional owners
August 9, 2023 | markets.businessinsider.com
Relmada Therapeutics (RLMD) Gets a Buy from Mizuho Securities
August 9, 2023 | finanznachrichten.de
Relmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
June 21, 2023 | fool.com
Relmada Therapeutics (NASDAQ: RLMD)
June 8, 2023 | finance.yahoo.com
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
June 3, 2023 | benzinga.com
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD
June 2, 2023 | finance.yahoo.com
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
May 24, 2023 | finance.yahoo.com
Relmada Therapeutics Insider Ups Holding By 62% During Year
May 24, 2023 | finance.yahoo.com
Relmada Therapeutics Insider Ups Holding By 62% During Year \
May 24, 2023 | finance.yahoo.com
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
May 15, 2023 | markets.businessinsider.com
SVB Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
May 12, 2023 | finanznachrichten.de
Relmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 | markets.businessinsider.com
Mizuho Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)
May 11, 2023 | msn.com
Relmada Therapeutics: Q1 Earnings Insights
May 11, 2023 | finance.yahoo.com
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 10, 2023 | benzinga.com
Earnings Preview For Relmada Therapeutics
May 9, 2023 | marketwatch.com
RLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
See More Headlines
Receive RLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLMD Company Calendar

Last Earnings
8/08/2023
Today
10/04/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RLMD
CUSIP
N/A
CIK
1553643
Web
www.relmada.com
Phone
(786) 629-1376
Fax
N/A
Employees
14
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$10.80
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+248.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-157,040,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-94.92%
Return on Assets
-86.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.40
Quick Ratio
11.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.67 per share
Price / Book
0.66

Miscellaneous

Outstanding Shares
30,100,000
Free Float
26,036,000
Market Cap
$93.31 million
Optionable
Optionable
Beta
0.13

Social Links

12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Sergio Traversa M.B.A. (Age 63)
    MBA, Pharm.D., PharmD, CEO & Director
    Comp: $719.04k
  • Mr. Maged S. Shenouda M.B.A. (Age 59)
    MBA, R.Ph, R.Ph., Chief Financial Officer
    Comp: $450.35k
  • Mr. Charles S. Ence CPA (Age 58)
    M.B.A., Chief Accounting & Compliance Officer
    Comp: $568.68k
  • Dr. Paolo Manfredi M.D. (Age 61)
    Ph.D., Chief Scientific Officer
  • Ms. Gina DiGuglielmo
    VP & Head of Clinical Operations
  • Dr. Marco Pappagallo M.D. (Age 64)
    Chief Clinical Officer
  • Mr. John Hixon
    Head of Commercial
  • Dr. Cedric O'Gorman M.B.A. (Age 47)
    M.D., MBA, Chief Medical Officer
  • Dr. Richard M. Mangano (Age 73)
    Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RLMD Stock - Frequently Asked Questions

Should I buy or sell Relmada Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RLMD, but not buy additional shares or sell existing shares.
View RLMD analyst ratings or view top-rated stocks.

What is Relmada Therapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued 12 month target prices for Relmada Therapeutics' stock. Their RLMD share price forecasts range from $4.00 to $25.00. On average, they predict the company's stock price to reach $10.80 in the next twelve months. This suggests a possible upside of 248.4% from the stock's current price.
View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts.

How have RLMD shares performed in 2023?

Relmada Therapeutics' stock was trading at $3.49 at the beginning of 2023. Since then, RLMD shares have decreased by 11.2% and is now trading at $3.10.
View the best growth stocks for 2023 here.

When is Relmada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RLMD earnings forecast.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced its earnings results on Tuesday, August, 8th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.08.

What ETF holds Relmada Therapeutics' stock ?

AdvisorShares Psychedelics ETF holds 150,158 shares of RLMD stock, representing 5.18% of its portfolio.

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the NASDAQ under the ticker symbol "RLMD."

How do I buy shares of Relmada Therapeutics?

Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $3.10.

How much money does Relmada Therapeutics make?

Relmada Therapeutics (NASDAQ:RLMD) has a market capitalization of $93.31 million. The company earns $-157,040,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

How can I contact Relmada Therapeutics?

Relmada Therapeutics' mailing address is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. The official website for the company is www.relmada.com. The company can be reached via phone at (786) 629-1376 or via email at mbecker@relmada.com.

This page (NASDAQ:RLMD) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -